BCLAF3

Across TCGA pan-cancer cohorts, BCLAF3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BCLAF3 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BCLAF3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BCLAF3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where BCLAF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	1.000	0.921	.006	15	view →
PDAC	OS	Median	II,III,IV	0.384	0.595	.030	6	view →
CCRCC	DFS	Median	All	0.945	0.715	.029	6	view →
LSCC	DFS	Median	All	0.974	0.909	.025	4	view →
HNSC	DFS	Quartile	III,IV	0.711	1.000	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BCLAF3–LUAD (OS)

Open the LUAD breakdown →